Completed PHASE2 INTERVENTIONAL NCT00190606

Efficacy and Safety of Duloxetine, Placebo and Pelvic Floor Muscle Training in Subjects With Stress Urinary Incontinence

Efficacy and Safety of Duloxetine Compared With Placebo,Pelvic Floor Muscle Training, and Combined Duloxetine/Pelvic Floor Muscle Training in Subjects With Moderate to Sever Stress Urinary Incontinence

Sponsor: Boehringer Ingelheim

Conditions Urinary Stress Incontinence

Interventions Duloxetine Imitation PFMT Pelvic Floor Muscle Training (PFMT) placebo

Updated 5 times since 2017 Last updated: Jan 24, 2007 Started: Jan 31, 2002 Completion: Apr 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Urinary Stress Incontinence, this trial is completed. The trial is conducted by Boehringer Ingelheim and has accumulated 5 data snapshots since 2002. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jan 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Boehringer Ingelheim
Eli Lilly and Company

Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nieuwegein, Netherlands
• Weston, United States